Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
Key Highlights
- ➤Intellia (NTLA) will present seven lonvo-z analyses at ACAAI 2026
- ➤Four-year follow-up data cover patients receiving a one-time 50 mg lonvo-z dose
- ➤FDA accepted lonvo-z’s BLA with Priority Review and March 10, 2027 PDUFA target
- ➤Investor webcast scheduled November 12 to discuss data and planned HAE commercial launch
* Oral presentations to include four-year follow-up data from patients who received a one-time 50 milligram (mg) dose of lonvo-z; insights on new hereditary angioedema (HAE) treatment goals * Poster presentations to include patient perspective about life after lonvo-z treatment * Intellia to host investor webcast on Thursday, November 12 at 10 a.m. ET CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced two oral presentations and five poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16 in Phoenix, Arizona. Intellia also announced that it will host an investor webcast on Thursday, November 12, at 8 a.m. MT / 10 a.m. ET to share highlights from the presentations, provide perspectives from HAE key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.
Get started
Create a free account to read the full story.